TITLE

ADA, ACC issue consensus statement on cardiometabolic risk

AUTHOR(S)
Haigh, Christen; Redberg, Rita F.
PUB. DATE
June 2008
SOURCE
Cardiology Today;Jun2008, Vol. 11 Issue 6, p36
SOURCE TYPE
Newspaper
DOC. TYPE
Proceeding
ABSTRACT
The article reports on the release of a consensus statement on recommendations for patients with cardiometabolic risk by the American Diabetes Association (ADA) and the American College of Cardiology (ACC), which convened at a consensus development conference from July 18-20, 2007. The recommendations in regard to dyslipoproteinemia include statin therapy, treatment goals addressing high lifetime risk, and clinical trials to determine safety and cost efficiency of pharmacologic therapy.
ACCESSION #
33119558

 

Related Articles

  • Correction.  // Endocrine Today;7/10/2008, Vol. 6 Issue 12, p5 

    Several corrections to the articles in the previous issues are presented including "ADA, ACC Issue Consensus Statement on Cardiometabolic Risk" and an article about TSH reference range.

  • Restenosis, Thrombosis, and Cost Debated at DES Symposium. Kahn, Jason // Journal of Interventional Cardiology;Aug2005, Vol. 18 Issue 4, p291 

    Discusses the in-stent restenosis, thrombosis, cost-effectiveness, stent-related inflammation at the annual meeting of the American College of Cardiology in the U.S. Complication of in-stent restenosis following drug-eluting stents implantation; Determination of the frequency of in-stent...

  • Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes. Pignone, Michael; Alberts, Mark J.; Colwell, John A.; Cushman, Mary; Inzucchi, Silvio E.; Mukherjee, Debabrata; Rosenson, Robert S.; Williams, Craig D.; Wilson, Peter W.; Kirkman, M. Sue // Diabetes Care;Jun2010, Vol. 33 Issue 6, p1395 

    The article focuses on the revised recommendations of the American Diabetes Association (ADA), American Heart Association (AHA) and the American College of Cardiology Foundation (ACCF) on aspirin therapy as a prevention strategy in people with diabetes at increased cardiovascular risk. It...

  • Cutting-Edge Data Presented at ADA 2011 Highlight the Diabetes-Cardiovascular Disease Link. Kuznar, Wayne // American Health & Drug Benefits;Sep2011, Vol. 4 Issue 6, p412 

    The article reports on topics which were discussed at the 2011 annual meeting of the American Diabetes Association, which was held in June in San Diego, California. Topics included the treatment of type two diabetes, improving insulin treatments for diabetes and diabetes education. The event was...

  • A Perspective on the New American College of Cardiology/American Heart Association Guidelines for Cardiovascular Risk Assessment. Kullo, Iftikhar J.; Trejo-Gutierrez, Jorge F.; Lopez-Jimenez, Francisco; Thomas, Randal J.; Allison, Thomas G.; Mulvagh, Sharon L.; Arruda-Olson, Adelaide M.; Hayes, Sharonne N.; Pollak, Amy W.; Kopecky, Stephen L.; Hurst, R. Todd // Mayo Clinic Proceedings;Sep2014, Vol. 89 Issue 9, p1244 

    The recently published American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for cardiovascular risk assessment provide equations to estimate the 10-year and lifetime atherosclerotic cardiovascular disease (ASCVD) risk in African Americans and non-Hispanic whites,...

  • Concepts and Controversies: The 2013 American College of Cardiology/American Heart Association Risk Assessment and Cholesterol Treatment Guidelines. Martin, Seth S.; Blumenthal, Roger S. // Annals of Internal Medicine;3/4/2014, Vol. 160 Issue 5, p356 

    The author reflects on clinical guidelines on cardiovascular disease risk assessment and cholesterol treatment issued by the American College of Cardiology and American Heart Association (ACC/AHA). The author discusses the guideline focused to guide decision making, expansion of the scope of...

  • Blood cholesterol treatment guidelines focus on four patient groups. GUTTMAN KRADER, CHERYL // Medical Economics;7/10/2014, Vol. 91 Issue 13, p17 

    The article reports on guidelines released by the American College of Cardiology/American Heart Association on November 2013, to help reduce the cholesterol levels in patients with atherosclerotic cardiovascular disease (ACD). Topics discussed include the results of randomized controlled trials...

  • Review: Framingham risk scores have variable accuracy in predicting CVD events in different patient populations: COMMENTARY. Havranek, Edward P. // ACP Journal Club;May/Jun2007, Vol. 146 Issue 3, p80 

    The author comments on a review of a study on the accuracy of Framingham risk assessments for predicting cardiovascular disease in different groups of patients. He asserted that researchers' predictions based on the Framingham risk scores overestimate in most unselected populations and...

  • CEO of ARCA biopharma to Present at American College of Cardiology 60th Annual Scientific Session and i2 Summit 2011.  // Biomedical Market Newsletter;5/21/2011, p219 

    The article announces that Michael Bristow, president and chief executive officer (CEO) at Arca Biopharma Inc., will be speaking at the American College of Cardiology 60th Annual Scientific Session and i2 Summit 2011 to be held in New Orleans, Louisiana. It notes that the event will be...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics